Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|September 22, 2026
ACT Brief: Patient-Site Interaction and Technology, AI Pilot Success Requires Discipline, and CagriSema Beats Lilly Drug
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine technology's real role in patient-site collaboration, why AI pilot failures stem from organization not innovation, and Novo's weight-loss drug results in competitive comparison.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part two of her DPHARM interview , Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone. Making it easier for patients and sites to interact effectively with each other requires designing systems around human relationships, not assuming interfaces alone will solve connection gaps. - In a
new feature article , Ken Getz and colleagues from Tufts CSDD and Evinova examined why most AI pilots fail, finding that poor outcomes trace to organizational factors, not technology: lack of strategic prioritization, inadequate data infrastructure, and missing governance. Organizations that succeed start with strength-based pilot selection in high-performing areas, establish clear governance upfront, and frame pilots within a comprehensive strategy rather than as isolated experiments. Novo Nordisk reported that CagriSema delivered 12.4% average weight loss in a late-stage trial, outperforming Eli Lilly's drug at comparable doses. A one-unit dose of Novo's combination therapy beat a five-unit dose of the competing treatment, while also showing non-inferior blood sugar reduction, representing a win for Novo ahead of its obesity franchise patent expiration after 2030.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
2
The Test Is the Ticket: Building Smarter Pathways to Clinical Trial Participation
3
Start Study Budgets Sooner With AI-Enabled Protocol Translation
4
Beyond Outreach: Structural Drivers of Representation in Clinical Trials
5